In the Spotlight

Celebrating CCR Careers: David D. Roberts, Ph.D.

David D. Roberts, Ph.D., a biochemist who identified a new pathway that controls cell responses to stress and developed approaches to improve cancer therapy by shutting it down, announces his retirement from the NCI.

Celebrating CCR Careers: Mark Gilbert, M.D.

Mark Gilbert, M.D., has been a neuro-oncologist for nearly four decades, working to find better treatments for people with rare brain and spine tumors. After nearly a decade at CCR as Chief of the Neuro-Oncology Branch, he is announcing his retirement.

New Milestones publication now available

Every year, CCR makes remarkable contributions to the understanding, detection, treatment and prevention of cancer. This issue of our annual publication, Milestones, features 10 of our top scientific advances from the past year. These discoveries fall everywhere on the spectrum from basic science to clinical research, ranging from a change in our understanding of how cells replicate and divide to the first FDA-approved treatment for a rare cancer based on the results of an NCI trial. Our researchers have developed a novel drug delivery system inspired by bacterial spores, identified prognostic gene signatures for patients with different cancers and gathered data over 30 years to show that an immunotherapy essentially cures a rare precancerous disease.

Celebrating CCR Careers: Jonathan R. Keller, Ph.D.

Jonathan R. Keller, Ph.D., an experimental hematologist who discovered interleukin-3 (IL-3) and explored the factors that give rise to leukemia, announces his retirement.

Howard A. Young, Ph.D., cutting the ribbon to celebrate the opening of his lab in the 1980s.

Celebrating CCR Careers: Howard A. Young, Ph.D.

Howard A. Young, Ph.D., spent over 40 years researching cytokine gene expression, especially interferons and how they contribute to chronic inflammation and disease. Now, he has announced his retirement.

Celebrating CCR Careers: William G. Stetler-Stevenson, M.D., Ph.D.

For over three decades, William G. Stetler-Stevenson, M.D., Ph.D., has been a leader in the field of tissue inhibitors of metalloproteinases (TIMP) biology and extracellular matrix regulation of cancer.

Celebrating CCR Careers: Allan M. Weissman, M.D.

Allan M. Weissman, M.D., who explored the essential underpinning of ubiquitin in cancer, announces his retirement from the NCI.

Celebrating CCR Careers: Kathleen Kelly, Ph.D.

Kathleen Kelly, Ph.D., who pioneered new frameworks for modeling and exploring how prostate cancer cells respond to anti-cancer drugs, announces her retirement from the NCI.

Celebrating CCR Careers: Kenneth H. Kraemer, M.D.

For more than fifty years, Kenneth H. Kraemer, M.D., has investigated the molecular underpinnings and clinical manifestations of xeroderma pigmentosum, a rare disease that makes children highly vulnerable to skin damage and cancers from ultraviolet radiation, at the NCI.

CCR Hosts “Frontiers in Basic Immunology” Symposium

CCR hosted a two-day international symposium, titled “Frontiers in Basic Immunology,” sponsored by the NCI Center of Excellence in Immunology (CEI). The program included a lineup of presentations from NCI and worldwide academic university speakers and a lively poster session.

Breadcrumb